Strategic Update II - 12 April 2021
CLINUVEL today announced its second Strategic Update, focussing on the decision processes underlying choices to expand and grow the Group of companies. A main goal of CLINUVEL’s growth is to integrate skills and functions in-house within the Group. Explore the Strategic Update II in detail below or download a full PDF summary here.
Targeted Technology Translation
CLINUVEL’s CEO, Dr. Philippe Wolgen, provides an update on the business, vision, objectives and strategy.
“The vision has always been to establish a company that’s diversified, sustainable, and fully integrated, with all functions in-house”
Objectives
The corporate objective is to establish a globally sustainable group with a constellation of prescriptive and healthcare products derived from melanocortins, originated from associated pharmacological concepts and addressing populations who yet remain unserved.
CLINUVEL strives for vertical integration of all key functions to ensure operational and financial independence, and synergy within the Group of companies.
Pharmaceutical
Division
Research & Development
CLINUVEL has focussed its R&D on melanocortins, associated hormones and peptides, polymers and technological expertise to
be applied for human use.
DNA repair Program
It is estimated that, globally, two billion individuals are susceptible to accelerated photodamage, leading to an increased risk of various forms of skin cancer.
Strategy and Planning: DNA Repair Program
CLINUVEL set out to provide evidence on the properties
of afamelanotide to photoprotect skin and
assist the repair of DNA damage.
CNS program - Arterial Ischaemic Stroke (AIS)
Scientific progress has demonstrated melanocortins as hormonal therapy to exert a positive effect on the central nervous system (CNS).
Further Clinical Use of Afamelanotide
SCENESSE® is being evaluated as the first systemically administered melanocortin for the pigment loss disorder, generalized vitiligo.
A Sixth Indication
The selection of a CLINUVEL-sponsored indication usually takes two to three years from identification to confirmation and acknowledgement by experts in the field.
Healthcare Solutions Division
Under the notion of Targeted Technology Translation (TTT), CLINUVEL aims to make technology, knowhow and expertise available for the greater benefit of broad populations.
CBM
Division
The CBM Division is responsible for composing unique narratives and engaging in long-term dialogue with new audiences.
Manufacturing Division
The Manufacturing Division will focus on the manufacturing of innovative, controlled-release systemic and topical formulations.